Back to News
Market Impact: 0.2
Forget Lilly and Novo: Pfizer Is Planning a Wave of Phase 3 Obesity Trials
Source: fool.com
Healthcare & BiotechCompany FundamentalsM&A & Restructuring
Eli Lilly leads the GLP-1 weight-loss market, while Novo Nordisk is working to regain lost market share. Pfizer discontinued its GLP-1 candidate but pivoted by acquiring another GLP-1 drug that remains in development; the article provides no deal value or clinical results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mixed
Sentiment Score
0.10
Ticker Sentiment
LLY0.60
NVO-0.35
PFE0.05
More News
- Decisive election. Dramatic stock swings. How we handled the market last week
- Ginkgo Bioworks: 3 Key Takeaways for Long-Term Investors
- Eli Lilly Just Raised Its 2026 Revenue Forecast by $5.5 Billion. Is the Stock Still a Buy?
- Binance CFO exits days after catastrophic $6 billion crypto hack
- Berkshire Hathaway more than doubles buybacks in third quarter as earnings decline
- Berkshire shares surge as Wall Street swoons amid AI fears